Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cavrotolimod + Pembrolizumab/Cemiplimab in Advanced Solid Tumors
NCT03684785Phase 2Terminated
- Sponsor
- Exicure, Inc.
- Start
- Dec 2018
- Primary completion
- Mar 2022
- Modality
- Antisense DNA, Nanoparticles, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of cavrotolimod in Merkel cell carcinoma (MCC), cutaneous squamous cell carcinoma (cSCC), melanoma, solid tumor, sponsored by Exicure, Inc.. Started Dec 2018; status: terminated.
02
Drugs
cavrotolimod
03
Conditions
Merkel cell carcinoma (MCC)cutaneous squamous cell carcinoma (cSCC)melanomasolid tumor
Beyond the preview
Go deeper on NCT03684785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03684785.